TipRanks
Advertisement
Advertisement
Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso
PremiumThe FlyHutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso
1M ago
Hutchmed price target lowered to $14 from $16 at Goldman Sachs
Premium
The Fly
Hutchmed price target lowered to $14 from $16 at Goldman Sachs
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100